1 month ago
31
Soumya Eswaran
Thu, July 30, 2026 astatine 8:21 AM CDT 3 min read
Meridian Funds, managed by ArrowMark Partners, released its second-quarter 2026 capitalist missive for "Meridian Small Cap Growth Fund". A transcript of the missive tin beryllium downloaded here. The U.S. marketplace saw a beardown rally successful the 2nd quarter, fueled by easing geopolitical tensions, falling lipid prices, and robust firm earnings. Growth stocks, particularly successful exertion and healthcare, led the charge, supported by AI-related investments from hyperscalers that added momentum. Meanwhile, accepted harmless havens similar golden declined. In this context, the Meridian Small Cap Growth Fund (the "Fund") achieved a 21.54% instrumentality for the 4th ending June 30, 2026. This lagged down its benchmark, the Russell 2000 Growth Index, which gained 25.71%, owed to origin and benignant headwinds—as high-beta and momentum stocks soared, its lower-volatility, quality-focused holdings underperformed. The Fund continues to prioritize prime businesses, hazard management, and downside protection, with portfolio adjustments driven by strategical allocation alternatively than weaknesses successful idiosyncratic holdings. In addition, delight cheque the Fund's apical 5 holdings to cognize its champion picks successful 2026.
In its Q2 2026 capitalist letter, Meridian Small Cap Growth Fund highlighted Definium Therapeutics, Inc. (NASDAQ:DFTX). Definium Therapeutics, Inc. (NASDAQ:DFTX), a objective biopharmaceutical company, contributed to the Fund's show during the quarter. On July 29, 2026, Definium Therapeutics, Inc. (NASDAQ:DFTX) closed astatine $42.16 per share, reflecting a marketplace capitalization of $5.6 billion. Definium Therapeutics, Inc. (NASDAQ:DFTX) posted a one-month instrumentality of -4.59%, portion its shares gained 363.81% implicit the past 52 weeks.
Meridian Small Cap Growth Fund stated the pursuing regarding Definium Therapeutics, Inc. (NASDAQ:DFTX) successful its Q2 2026 capitalist update:
"Definium Therapeutics, Inc. (NASDAQ:DFTX) is simply a clinical-stage biopharmaceutical institution processing a rapid-acting, azygous dose LSD-based therapy for large depressive upset and generalized anxiousness disorder, administered successful a monitored objective setting. We ain it for its perchance best-in-class illustration successful large, underserved mental-health markets and a pipeline approaching respective pivotal readouts. Shares much than doubled during the 4th aft the institution reported affirmative topline results from its pivotal Phase 3 survey successful large depressive disorder, which comfortably exceeded the efficacy barroom investors had acceptable and showed a durable attraction effect with precocious remission rates versus placebo. The readout meaningfully de-risked the programme and acceptable up the archetypal generalized-anxiety-disorder readout, expected shortly, arsenic the adjacent imaginable catalyst."
English (CA) · 
English (US) · 
Spanish (MX) ·